Compare BLLN & KFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLLN | KFY |
|---|---|---|
| Founded | 2016 | 1969 |
| Country | United States | United States |
| Employees | 713 | N/A |
| Industry | Medical Specialities | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.4B |
| IPO Year | N/A | 1998 |
| Metric | BLLN | KFY |
|---|---|---|
| Price | $80.12 | $62.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $129.57 | $71.33 |
| AVG Volume (30 Days) | 318.7K | ★ 532.8K |
| Earning Date | 03-04-2026 | 03-09-2026 |
| Dividend Yield | N/A | ★ 3.11% |
| EPS Growth | N/A | ★ 42.41 |
| EPS | N/A | ★ 3.84 |
| Revenue | N/A | ★ $1,819,519,000.00 |
| Revenue This Year | $45.89 | $7.14 |
| Revenue Next Year | $30.17 | $3.32 |
| P/E Ratio | ★ N/A | $16.13 |
| Revenue Growth | N/A | ★ 12.20 |
| 52 Week Low | $61.96 | $58.27 |
| 52 Week High | $138.70 | $78.50 |
| Indicator | BLLN | KFY |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 51.58 |
| Support Level | $63.98 | $62.46 |
| Resistance Level | $86.01 | $64.35 |
| Average True Range (ATR) | 5.61 | 1.79 |
| MACD | 1.30 | 0.19 |
| Stochastic Oscillator | 75.47 | 68.02 |
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.